120 related articles for article (PubMed ID: 27010394)
1. Efficacy and safety of re-induction therapy with bevacizumab and paclitaxel for metastatic breast cancer.
Yoshinami T; Yagi T; Okuno J; Kittaka N; Ishitobi M; Sugimoto N; Nakayama T; Tamaki Y; Imamura F
Breast Cancer; 2017 Jan; 24(1):147-151. PubMed ID: 27010394
[TBL] [Abstract][Full Text] [Related]
2. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.
Aogi K; Masuda N; Ohno S; Oda T; Iwata H; Kashiwaba M; Fujiwara Y; Kamigaki S; Ito Y; Ueno T; Takashima S
Breast Cancer Res Treat; 2011 Oct; 129(3):829-38. PubMed ID: 21805309
[TBL] [Abstract][Full Text] [Related]
3. A Real-World Retrospective Cohort Study of Combined Therapy with Bevacizumab and Paclitaxel in Japanese Patients with Metastatic Breast Cancer.
Yamada H; Inoue K; Nagai SE; Nakai M; Arisawa F; Ueda H; Saito T; Ninomiya J; Kuroda T; Sakurai T; Kodama H; Kimizuka K; Hata S; Kai T; Kurosumi M;
J Nippon Med Sch; 2017; 84(5):215-223. PubMed ID: 29142182
[TBL] [Abstract][Full Text] [Related]
4. Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study.
Ferrero JM; Hardy-Bessard AC; Capitain O; Lortholary A; Salles B; Follana P; Herve R; Deblock M; Dauba J; Atlassi M; Largillier R
Cancer; 2016 Oct; 122(20):3119-3126. PubMed ID: 27412268
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
[TBL] [Abstract][Full Text] [Related]
6. First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study.
Schneeweiss A; Förster F; Tesch H; Aktas B; Gluz O; Geberth M; Hertz-Eichenrode MM; Schönegg W; Schumacher C; Kutscheidt A; Kiewitz C; Klawitter S; Schmidt M
Anticancer Res; 2016 Mar; 36(3):967-74. PubMed ID: 26976985
[TBL] [Abstract][Full Text] [Related]
7. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
Rochlitz C; Bigler M; von Moos R; Bernhard J; Matter-Walstra K; Wicki A; Zaman K; Anchisi S; Küng M; Na KJ; Bärtschi D; Borner M; Rordorf T; Rauch D; Müller A; Ruhstaller T; Vetter M; Trojan A; Hasler-Strub U; Cathomas R; Winterhalder R;
BMC Cancer; 2016 Oct; 16(1):780. PubMed ID: 27724870
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
[TBL] [Abstract][Full Text] [Related]
9. Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators.
Inoue K; Ninomiya J; Saito T; Kimizuka K; Kurosumi M
BMC Cancer; 2018 Jun; 18(1):671. PubMed ID: 29925345
[TBL] [Abstract][Full Text] [Related]
10. [Third- and Fourth-Line Chemotherapies including Paclitaxel and Bevacizumab for Metastatic Breast Cancer].
Sakamoto M; Nio Y; Imai S; Uesugi K; Tamaoki M; Tamaoki M
Gan To Kagaku Ryoho; 2017 Jul; 44(7):579-584. PubMed ID: 28790261
[TBL] [Abstract][Full Text] [Related]
11. [A Case of Drug-Induced Lung Injury Associated with Paclitaxel plus Bevacizumab Therapy].
Yamaguchi Y; Tada Y; Takaya S; Iwamoto A; Yamashiro Y; Shibata S; Ishiguro M; Nishidoi H
Gan To Kagaku Ryoho; 2016 Jun; 43(6):781-4. PubMed ID: 27306821
[TBL] [Abstract][Full Text] [Related]
12. [A Retrospective Case Study of Combination Chemotherapy with Bevacizumab for Recurrent Ovarian Cancer].
Hori K; Tsuruta T; Odani C; Ono H; Ohkubo R; Shimoji K; Murakami J; Nakagawa M; Tashima L; Ito K
Gan To Kagaku Ryoho; 2016 Oct; 43(10):1197-1200. PubMed ID: 27760937
[TBL] [Abstract][Full Text] [Related]
13. Final overall survival results and effect of prolonged (≥ 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial.
Smith I; Pierga JY; Biganzoli L; Cortes-Funes H; Thomssen C; Saracchini S; Nisenbaum B; Pelaez I; Duenne AA; Pritchard KI
Breast Cancer Res Treat; 2011 Nov; 130(1):133-43. PubMed ID: 21830015
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.
Miles D; Cameron D; Bondarenko I; Manzyuk L; Alcedo JC; Lopez RI; Im SA; Canon JL; Shparyk Y; Yardley DA; Masuda N; Ro J; Denduluri N; Hubeaux S; Quah C; Bais C; O'Shaughnessy J
Eur J Cancer; 2017 Jan; 70():146-155. PubMed ID: 27817944
[TBL] [Abstract][Full Text] [Related]
15. First-line bevacizumab-paclitaxel in 220 patients with metastatic breast cancer: results from the AVAREG study.
Dank M; Budi L; Piko B; Mangel L; Erfan J; Cseh J; Ruzsa A; Landherr L
Anticancer Res; 2014 Mar; 34(3):1275-80. PubMed ID: 24596372
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab Exacerbates Paclitaxel-Induced Neuropathy: A Retrospective Cohort Study.
Matsuoka A; Maeda O; Mizutani T; Nakano Y; Tsunoda N; Kikumori T; Goto H; Ando Y
PLoS One; 2016; 11(12):e0168707. PubMed ID: 27992556
[TBL] [Abstract][Full Text] [Related]
17. Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study.
Delva R; Pienkowski T; Tubiana N; Vanhoefer U; Longerey B; Douville I
Cancer Chemother Pharmacol; 2007 May; 59(6):703-9. PubMed ID: 17021821
[TBL] [Abstract][Full Text] [Related]
18. A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy.
Mizota A; Shitara K; Kondo C; Nomura M; Yokota T; Takahari D; Ura T; Muro K
Oncology; 2011; 81(3-4):237-42. PubMed ID: 22094594
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
Miller K; Wang M; Gralow J; Dickler M; Cobleigh M; Perez EA; Shenkier T; Cella D; Davidson NE
N Engl J Med; 2007 Dec; 357(26):2666-76. PubMed ID: 18160686
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer.
Link JS; Waisman JR; Nguyen B; Jacobs CI
Clin Breast Cancer; 2007 Oct; 7(10):779-83. PubMed ID: 18021479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
